PriceTargets.com logo

Citius Oncology - CTOR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 235.57%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.89 As of 04/29/2025 04:59 PM ET
▲ +0.1939 (27.70%)

This chart shows the closing price for CTOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$0.89Closing price on 04/29/25:
Get New Citius Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTOR

Analyst Price Target is $3.00
▲ +235.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Citius Oncology in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 235.57% upside from the last price of $0.89.

This chart shows the closing price for CTOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
8/2411/242/254/255/26$0.40$1.05$1.70$2.35$3Closing price on 04/29/25: $0.89High$3.00Average$3.00Low$3.00




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Citius Oncology.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/6/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/27/2024Maxim GroupInitiated CoverageBuy$3.00
(Data available from 4/29/2020 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2025

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

Citius Oncology logo
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Read More

Today's Range

Now: $0.89
Low: $0.69
High: $0.89

50 Day Range

MA: $0.80
Low: $0.57
High: $1.25

52 Week Range

Now: $0.89
Low: $0.55
High: $4.42

Volume

191,515 shs

Average Volume

1,193,339 shs

Market Capitalization

$63.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Citius Oncology?

The following Wall Street research analysts have issued stock ratings on Citius Oncology in the last year: Maxim Group.
View the latest analyst ratings for CTOR.

What is the current price target for Citius Oncology?

0 Wall Street analysts have set twelve-month price targets for Citius Oncology in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 235.6%. Maxim Group has the highest price target set, predicting CTOR will reach $3.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Citius Oncology in the next year.
View the latest price targets for CTOR.

What is the current consensus analyst rating for Citius Oncology?

Citius Oncology currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTOR will outperform the market and that investors should add to their positions of Citius Oncology.
View the latest ratings for CTOR.

What other companies compete with Citius Oncology?

Other companies that are similar to Citius Oncology include Gossamer Bio, DiaMedica Therapeutics, Inventiva, MediWound and Eledon Pharmaceuticals. Learn More about companies similar to Citius Oncology.

How do I contact Citius Oncology's investor relations team?

Citius Oncology's physical mailing address is 420 LEXINGTON AVE SUITE 2446, NEW YORK NY, 10017. The company's listed phone number is 347-627-0058 and its investor relations email address is ir@citiusonc.com. The official website for Citius Oncology is www.citiusonc.com. Learn More about contacing Citius Oncology investor relations.